DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been given an average recommendation of “Moderate Buy” by the ten research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $35.3750.

Several equities research analysts have weighed in on DBVT shares. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a research report on Wednesday, December 17th. HC Wainwright set a $40.00 target price on DBV Technologies in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Citizens Jmp increased their price objective on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th. Finally, Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st.

Insiders Place Their Bets

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the transaction, the insider directly owned 7,303,369 shares of the company’s stock, valued at approximately $30,601,116.11. The trade was a 15.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 3,369,627 shares of company stock valued at $15,489,908 in the last quarter. Insiders own 1.44% of the company’s stock.

Institutional Investors Weigh In On DBV Technologies

A number of large investors have recently modified their holdings of DBVT. Vivo Capital LLC bought a new position in DBV Technologies in the second quarter worth about $9,659,000. Adage Capital Partners GP L.L.C. bought a new stake in DBV Technologies during the 2nd quarter valued at approximately $9,659,000. MPM Bioimpact LLC purchased a new position in shares of DBV Technologies during the 2nd quarter worth approximately $9,649,000. Octagon Capital Advisors LP bought a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,315,000. Finally, Millennium Management LLC raised its position in shares of DBV Technologies by 26.1% in the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after acquiring an additional 69,849 shares in the last quarter. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $21.26 on Friday. DBV Technologies has a 52-week low of $3.82 and a 52-week high of $26.18. The company’s 50 day moving average price is $19.35 and its 200-day moving average price is $14.39. The stock has a market capitalization of $853.80 million, a price-to-earnings ratio of -4.11 and a beta of -0.98.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.